Core Insights - The global irritable bowel syndrome (IBS) treatment market is projected to grow from USD 3.78 billion in 2025 to USD 7.31 billion by 2033, with a CAGR of 8.6% during the forecast period (2025-2033) [1][15]. Market Dynamics - The rise in the geriatric population is driving demand for IBS treatments, as older individuals are more susceptible to gastrointestinal disorders [4][5]. - Emerging economies like China and India present significant growth opportunities due to improved healthcare infrastructure and rising awareness of IBS treatments [6][7]. Regional Analysis - North America holds the largest market share for IBS treatment, with an estimated CAGR of 7.3% during the forecast period, driven by advanced treatment products and increasing patient awareness [8][9]. - Europe is expected to grow at a CAGR of 8.1%, influenced by lifestyle changes and the presence of major market players [10][11]. Market Segmentation - The IBS treatment market is segmented by product, with Rifaximin leading and projected to grow at a CAGR of 9.4% [15]. - By type, IBS with Diarrhea (IBS-D) dominates the market, expected to grow at a CAGR of 9.0% [15]. - Distribution channels show Drug Stores and Retail Pharmacies holding the highest market share, with a predicted CAGR of 7.5% [15]. Competitive Landscape - Key players in the IBS treatment market include Abbott, Synergy Pharma, Mallinckrodt, and Novartis AG, among others [15].

As filed with the Securities and Exchange Commission on February 14, 2024 Registration No. 333-269188 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 13 to FORM S-1 REGISTRATION STATEMENT under The Securities Act of 1933 CHROMOCELL THERAPEUTICS CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2836 86-3335449 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer ...